GAITHERSBURG, Md.,
April 7, 2014 (GLOBE NEWSWIRE) -- Novavax,
Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of recombinant nanoparticle vaccines and adjuvants, today announced
the appointment of Cynthia N. Oliver, Ph.D. to the position of
Senior Vice President, Process Development Operations, effective
April 8, 2014. Dr. Oliver will be responsible for all process
development activities, with a specific focus on the company's RSV
F-protein nanoparticle, seasonal influenza and pandemic influenza
vaccine candidates.
Dr. Oliver has been a consultant of Novavax since 2011 where her
significant expertise and experiences have helped the Company
formulate and execute on critical process development strategies.
From 1993 until 2010, Dr. Oliver held a variety of positions,
including Vice President, Process Biochemistry and Formulation
Sciences at Medimmune, Inc., with responsibilities that included
vaccines, proteins, monoclonal antibodies and small molecules,
including the commercial products Synagis® and FluMist®. Prior to
MedImmune, she had similar responsibilities at Merck Research
Laboratories, and spent a number of years working at the National
Institutes of Health in the National Heart, Lung and Blood
Institute. She earned her doctorate from Johns Hopkins, her masters
from University of Massachusetts, and her bachelor's degree from
Connecticut College.
"At Novavax, successful process development is critical to the
ongoing development of our novel vaccines and it serves as the
foundation upon which a consistent, GMP commercial manufacturing
process is built. Cindy's extensive experience, industry knowledge
and managerial aptitude complement our ongoing efforts to bring our
RSV, seasonal influenza and pandemic influenza vaccine candidates
to licensure," said Stan Erck, President and CEO of Novavax, Inc.
"After working with us as a consultant for three years, I am
delighted that Cindy has agreed to join Novavax to lead our process
development efforts."
Dr. Oliver remarked, "Novavax' progress and success in Phase 2
clinical trials evidences its commitment to bringing important, and
in the case of RSV, industry-leading vaccines to the market. I have
been delighted to consult with Novavax to this stage, and am
equally delighted to head up our efforts to develop safe, high
quality vaccines and state-of-the-art vaccine production. Novavax'
approach to developing these and other, earlier-stage preclinical
vaccine candidates, has tremendous commercial potential, and I am
honored to lead the process development function that supports this
exciting technology."
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical
company creating novel vaccines and vaccine adjuvants to address a
broad range of infectious diseases worldwide. Using innovative
proprietary recombinant protein nanoparticle vaccine technology,
the company produces vaccine candidates to efficiently and
effectively respond to both known and newly emergent diseases.
Additional information about Novavax is available on the company's
website, novavax.com.
Forward-Looking Statements
Statements herein relating to the future of
Novavax and the ongoing development of its vaccine and adjuvant
products are forward-looking statements. Novavax cautions that
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include those identified under the
heading "Risk Factors" in the Novavax Annual Report on Form 10-K
for the year ended December 31, 2013, and filed with the Securities
and Exchange Commission (SEC). Investors are cautioned not to place
considerable reliance on the forward-looking statements contained
in this press release. You are encouraged to read company filings
with the SEC, available at sec.gov, for a discussion of these and
other risks and uncertainties. The forward-looking statements in
this press release speak only as of the date of this document, and
the company undertakes no obligation to update or revise any of the
statements. The company's business is subject to substantial risks
and uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
|